Trial Profile
A phase 2a study of anti-CD3 oral immunotherapy in patients with ulcerative colitis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Muromonab CD3 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 30 Sep 2015 New trial record